Epithalamin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-07-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.
Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.
The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.
Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22N4O9 | Derived from the four constituent residues |
| Molecular mass | About 390.35 Da | Monoisotopic value, confirmed by mass spectrometry |
| Residue sequence | Ala-Glu-Asp-Gly | Read from the N-terminus to the C-terminus |
| Common synonyms | Epithalon; AEDG | Both forms appear in reference catalogues |
| Net charge near neutral pH | Negative | Two acidic side chains give a low isoelectric point |
The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.
Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.
Epitalon is a synthetic tetrapeptide whose sequence is alanine-glutamate-aspartate-glycine, written in single-letter code as AEDG. The four residues are joined by three peptide bonds, giving a linear backbone with no branching and no disulfide bridges. Its calculated molecular mass for the free form is approximately 390.3 daltons, a figure that rises when the compound is supplied as an acetate or trifluoroacetate salt. Because the chain is short, the molecule is defined entirely by its residue order rather than by any folded three-dimensional structure.
The compound is described in the literature as a derivative of epithalamin, a preparation obtained from bovine pineal tissue. Work on this peptide family was carried out mainly by a research group in Saint Petersburg beginning in the 1980s, and the substance was later registered for clinical use in Russia under the name Epitalon. Outside that region it is generally treated as a research chemical rather than an approved medicine. Statements about its biological activity rest on a relatively small number of studies, and independent replication remains limited.
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
Interest in epitalon is usually discussed within the broader field of short peptide bioregulators, a category that includes other synthetic di-, tri-, and tetrapeptides studied by the same research group. These compounds share a common rationale: that small fragments of tissue-derived proteins can retain biological activity and can be produced reproducibly. The category as a whole remains outside mainstream pharmacological consensus, and epitalon specifically has a limited presence in independent, non-Russian research literature, which shapes how its evidence base is described.
Epitalon is a synthetic tetrapeptide with the amino acid sequence alanine-glutamate-aspartate-glycine, abbreviated Ala-Glu-Asp-Gly or AEDG. It was developed by the Russian researcher Vladimir Khavinson and colleagues during work on peptide bioregulators derived from the pineal gland. The compound is short enough to be produced by standard solid-phase peptide synthesis and is typically handled as a lyophilized white powder. Its small size distinguishes it from larger pineal peptides such as epithalamin, a complex extract from which the tetrapeptide was conceptually derived.
1993/654) Rent Act 1977 (Forms etc.) (Amendment) Regulations 1993 (S.I. 1993/655) Rent Book (Forms of Notice) (Amendment) Regulations 1993 (S.I. 1993/656) Assured Tenancies and Agricultural Occupancies (Rent Information) (Amendment) Order 1993 (S.I. 1993/657) Local Government Finance (Housing) (Consequential Amendments) (Scotland) Order 1993 (S.I. 1993/658) Rent Assessment Committees (Scotland) (Consequential Amendments) Regulations 1993 (S.I. 1993/659) Child Support (Amendments to Primary Legislation) (Scotland) Order 1993 (S.I. 1993/660) A66 Trunk Road (Stainmore-Banks Gate De-Trunking) Order 1993 (S.I. 1993/661) A66 Trunk Road (Stainmore-Banks Gate Improvement) Order 1993 (S.I. 1993/662) County of Wiltshire (Electoral Arrangements) Order 1993 (S.I. 1993/679) M621 To M1 Link Roads (and Connecting Roads) Scheme 1993 (S.I. 1993/681) Nuclear Installations (Application of Security Provisions) Order 1993 (S.I. 1993/687) Council Tax Benefit (General) Amendment Regulations 1993 (S.I. 1993/688) Council Tax Benefit (Permitted Total) Order 1993 (S.I. 1993/689) Adoption (Designation of Overseas Adoptions) (Variation) Order 1993 (S.I. 1993/690) Cheshire, Lancashire and Merseyside (County and Metropolitan Borough Boundaries) Order 1993 (S.I. 1993/691) War Pensions (Miscellaneous Amendments) Order 1993 (S.I. 1993/692) Guy's and St Thomas' National Health Service Trust (Establishment) Order 1993 (S.I. 1993/693) Lewisham Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/694) St Thomas' Hospital National Health Service Trust Dissolution Order 1993 (S.I.
A snakebite is an injury caused by the bite of a snake. Most snake species are non-venomous, but bites from venomous snakes may result in envenomation, in which venom is injected into the victim. A common sign of a bite from a venomous snake is the presence of two puncture wounds from the animal's fangs. Envenomation may cause redness, swelling, and severe pain around the bite, which may take up to an hour to develop. Vomiting, blurred vision, tingling of the limbs, and sweating may result. Most bites are on the hands, arms, or legs. Fear following a bite is common with symptoms of a racing heart and feeling faint. The venom may cause bleeding, kidney failure, a severe allergic reaction, tissue death around the bite, or breathing problems. Bites may result in the loss of a limb or other chronic problems or even death. The outcome depends on the type of snake, the area of the body bitten, the amount of snake venom injected, the general health of the person bitten, and whether or not anti-venom serum has been administered in a timely manner. Problems are often more severe in children than adults, due to their smaller size. Allergic reactions to snake venom can further complicate outcomes and can include anaphylaxis, requiring additional treatment and in some cases resulting in death. Snakes bite acts both as a method of hunting and as a means of protection. Risk factors for bites include working outside with one's hands such as in farming, forestry, and construction.
=== Witnesses === Afraid of being kidnapped and missing Mendonça, one of the boy's friend at school tried to commit suicide, two months after the disappearance. In the crime's reconstitution, Dias could not explain what he did between 14 (2 P.M) and 18 (6 P.M) hours on the day Mendonça disappeared. With the reconstitution it was proven that the investigation let leads and important witnesses slip by. The inspectors did not want to explain to the press the reason why they devalued Alcina Dias' testimony. A man that worked in a gas station guaranteed that at the time of the disappearance he saw Mendonça, in the centre of the village of Lousada, walking next to two other boys. The court questioned the witness about his statements to the GNR the day following the disappearance, where he said he saw two children passed by on bikes, but that neither was Mendonça. The witness insisted that he could not remember giving the testimony to GNR, even thought his signature was in the records. They also heard a witness that said they saw Mendonça's bicycle at 16 (4 P.M) hours. Without being identified, a boy that was 14 at the time of the disappearance, told RTP that PJ did not value the different testimonies given to the police. The witness, along with four other young people, was waiting for Mendonça to arrive to play football. When Mendonça got there he said he was not going to play anymore, hid his bike and got in the car. In 2003, in the Casa Pia Process, a man said that he was with Mendonça in a pension for sexual meetings, in the end of January 2001.
Exosomal polycystin-1-interacting protein is a protein that, in humans, is encoded by the EPCIP gene. EPCIP is found on human chromosome 21, and it is thought to be expressed in tissues of the brain and reproductive organs. Additionally, EPCIP is highly expressed in ovarian surface epithelial cells during normal regulation, but is not expressed in cancerous ovarian surface epithelial cells.
== History == Crisaborole was developed by Anacor Pharmaceuticals for the topical treatment of psoriasis. During preclinical and clinical development, crisaborole was called AN2728 and PF-06930164. The drug was assumed to be potential $2bn-a-year blockbuster, when Pfizer acquired Anacor Pharmaceuticals. However, the drug was commercially not successful, reaching only US$147 million in sales in 2018, and US$138 million in sales in 2019. Crisaborole was approved for use in the United States in December 2016 and for use in Canada in June 2018. The safety and efficacy of crisaborole were established in two placebo-controlled trials with a total of 1,522 participants ranging in age from two years of age to 79 years of age, with mild to moderate atopic dermatitis. In both trials participants received treatment with either crisaborole or placebo twice daily for 28 days. Neither the participants nor the health care providers knew which treatment was being given until after the trials were completed. Overall, participants receiving crisaborole achieved greater response with clear or almost clear skin after 28 days of treatment. The trials were conducted in the US. Crisaborole, approved for the treatment of mild to moderate atopic dermatitis in the European Union, has been rapidly withdrawn from the European market (March 2020 - February 2022).
Sources: en.wikipedia.org
=== Not radioactive === Irradiated food does not become radioactive; only particle energies that are incapable of causing significant induced radioactivity are used for food irradiation. In the United States this limit is 4 mega electron volts (MEV) for electron beams and x-ray sources—cobalt-60 or caesium-137 sources are never energetic enough to induce radioactivity. Particles below this energy can never be energetic enough to modify the nucleus of the targeted atom in the food, regardless of how many particles hit the target material, and so radioactivity can not be induced.
If the temperature is decreased, the metabolic activity in the fish from microbial or autolytic processes can be reduced or stopped. This is achieved by refrigeration where the temperature is dropped to about 0 °C, or freezing where the temperature is dropped below -18 °C. On fishing vessels, the fish are refrigerated mechanically by circulating cold air or by packing the fish in boxes with ice. Forage fish, which are often caught in large numbers, are usually chilled with refrigerated or chilled seawater. Once chilled or frozen, the fish need further cooling to maintain the low temperature. There are key issues with fish cold store design and management, such as how large and energy efficient they are, and the way they are insulated and palletized. An effective method of preserving the freshness of fish is to chill with ice by distributing ice uniformly around the fish. It is a safe cooling method that keeps the fish moist and in an easily stored form suitable for transport. It has become widely used since the development of mechanical refrigeration, which makes ice easy and cheap to produce. Ice is produced in various shapes; crushed ice and ice flakes, plates, tubes and blocks are commonly used to cool fish. Particularly effective is slurry ice, made from microcrystals of ice formed and suspended within a solution of water and a freezing point depressant, such as common salt. A more recent development is pumpable ice technology.
===== MeSH D08.811.277.352 – esterases (EC 3.1) ===== MeSH D08.811.277.352.100 – carboxylic-ester hydrolases MeSH D08.811.277.352.100.050 – acetylesterase MeSH D08.811.277.352.100.100 – carboxylesterase MeSH D08.811.277.352.100.150 – cholesterol esterase MeSH D08.811.277.352.100.170 – cholinesterases MeSH D08.811.277.352.100.170.176 – acetylcholinesterase MeSH D08.811.277.352.100.170.250 – butyrylcholinesterase MeSH D08.811.277.352.100.170.710 – pseudocholinesterase MeSH D08.811.277.352.100.220 – dehydroascorbatase MeSH D08.811.277.352.100.400 – lipase MeSH D08.811.277.352.100.400.745 – pancrelipase MeSH D08.811.277.352.100.430 – lipoprotein lipase MeSH D08.811.277.352.100.500 – monoacylglycerol lipases MeSH D08.811.277.352.100.550 – naphthol as d esterase MeSH D08.811.277.352.100.680 – phospholipases MeSH D08.811.277.352.100.680.510 – lysophospholipase MeSH D08.811.277.352.100.680.750 – phospholipases a MeSH D08.811.277.352.100.680.750.500 – 1-alkyl-2-acetylglycerophosphocholine esterase MeSH D08.811.277.352.335 – deoxyribonucleases MeSH D08.811.277.352.335.350 – endodeoxyribonucleases MeSH D08.811.277.352.335.350.025 – aspergillus nuclease s1 MeSH D08.811.277.352.335.350.137 – deoxyribonuclease (pyrimidine dimer) MeSH D08.811.277.352.335.350.250 – deoxyribonuclease i MeSH D08.811.277.352.335.350.250.900 – streptodornase and streptokinase MeSH D08.811.277.352.335.350.275 – deoxyribonuclease iv (phage t4-induced) MeSH D08.811.277.352.335.350.300 – dna restriction enzymes MeSH D08.811.277.352.335.350.300.250 – deoxyribonucleases, type i site-specific MeSH D08.811.277.352.335.350.300.260 – deoxyribonucleases, type ii site-specific MeSH D08.811.277.352.335.350.300.260.240 – deoxyribonuclease bamhi MeSH D08.811.277.352.335.350.300.260.250 – deoxyribonuclease ecori MeSH D08.811.277.352.335.350.300.260.260 – deoxyribonuclease hindiii MeSH D08.811.277.352.335.350.300.260.300 – deoxyribonuclease hpaii MeSH D08.811.277.352.335.350.300.270 – deoxyribonucleases, type iii site-specific MeSH D08.811.277.352.335.350.400 – holliday junction resolvases MeSH D08.811.277.352.335.350.500 – micrococcal nuclease MeSH D08.811.277.352.335.375 – exodeoxyribonucleases MeSH D08.811.277.352.335.375.750 – exodeoxyribonuclease V MeSH D08.811.277.352.355 – endonucleases MeSH D08.811.277.352.355.325 – endodeoxyribonucleases MeSH D08.811.277.352.355.325.025 – aspergillus nuclease s1 MeSH D08.811.277.352.355.325.300 – dna restriction enzymes MeSH D08.811.277.352.355.325.300.250 – deoxyribonucleases, type i site-specific MeSH D08.811.277.352.355.325.300.260 – deoxyribonucleases, type ii site-specific MeSH D08.811.277.352.355.325.300.260.240 – deoxyribonuclease bamhi MeSH D08.811.277.352.355.325.300.260.250 – deoxyribonuclease ecori MeSH D08.811.277.352.355.325.300.260.260 – deoxyribonuclease hindiii MeSH D08.811.277.352.355.325.300.260.300 – deoxyribonuclease hpaii MeSH D08.811.277.352.355.325.300.270 – deoxyribonucleases, type iii site-specific MeSH D08.811.277.352.355.325.350 – flap endonucleases MeSH D08.811.277.352.355.325.400 – holliday junction resolvases MeSH D08.811.277.352.355.325.500 – micrococcal nuclease MeSH D08.811.277.352.355.350 – endoribonucleases MeSH D08.811.277.352.355.350.025 – aspergillus nuclease s1 MeSH D08.811.277.352.355.350.500 – micrococcal nuclease MeSH D08.811.277.352.355.350.700 – ribonuclease h, calf thymus MeSH D08.811.277.352.355.350.715 – ribonuclease, pancreatic MeSH D08.811.277.352.355.350.725 – ribonuclease t1 MeSH D08.811.277.352.355.350.810 – RNA-induced silencing complex MeSH D08.811.277.352.365 – exonucleases MeSH D08.811.277.352.365.290 – exodeoxyribonucleases MeSH D08.811.277.352.365.300 – exoribonucleases MeSH D08.811.277.352.640 – phosphoric diester hydrolases MeSH D08.811.277.352.640.050 – annexin A3 MeSH D08.811.277.352.640.125 – 3',5'-cyclic-GMP phosphodiesterase MeSH D08.811.277.352.640.150 – 3',5'-cyclic-nucleotide phosphodiesterase MeSH D08.811.277.352.640.160 – 2',3'-cyclic-nucleotide phosphodiesterases MeSH D08.811.277.352.640.295 – glycerophosphoinositol inositolphosphodiesterase MeSH D08.811.277.352.640.430 – phosphodiesterase i MeSH D08.811.277.352.640.700 – phospholipases MeSH D08.811.277.352.640.700.700 – phospholipase c MeSH D08.811.277.352.640.700.700.500 – phosphatidylinositol diacylglycerol-lyase MeSH D08.811.277.352.640.700.700.750 – phospholipase c gamma MeSH D08.811.277.352.640.700.710 – phospholipase d MeSH D08.811.277.352.640.750 – sphingomyelin phosphodiesterase MeSH D08.811.277.352.650 – phosphoric monoester hydrolases MeSH D08.811.277.352.650.025 – acid phosphatase MeSH D08.811.277.352.650.035 – alkaline phosphatase MeSH D08.811.277.352.650.200 – fructose-bisphosphatase MeSH D08.811.277.352.650.225 – glucose-6-phosphatase MeSH D08.811.277.352.650.300 – histidinol-phosphatase MeSH D08.811.277.352.650.575 – 4-nitrophenylphosphatase MeSH D08.811.277.352.650.600 – nucleotidases MeSH D08.811.277.352.650.600.600 – 5'-nucleotidase MeSH D08.811.277.352.650.620 – phosphatidate phosphatase MeSH D08.811.277.352.650.622 – phosphofructokinase-2 MeSH D08.811.277.352.650.625 – phosphoprotein phosphatase MeSH D08.811.277.352.650.625.150 – calcineurin MeSH D08.811.277.352.650.625.300 – glycogen-synthase-d phosphatase MeSH D08.811.277.352.650.625.475 – myosin light-chain phosphatase MeSH D08.811.277.352.650.625.650 – phosphorylase phosphatase MeSH D08.811.277.352.650.625.700 – protein-tyrosine-phosphatase MeSH D08.811.277.352.650.625.700.150 – antigens, cd45 MeSH D08.811.277.352.650.625.700.200 – cdc25 phosphatase MeSH D08.811.277.352.650.625.725 – pyruvate dehydrogenase (lipoamide)-phosphatase MeSH D08.811.277.352.650.700 – 6-phytase MeSH D08.811.277.352.650.850 – pten phosphohydrolase MeSH D08.811.277.352.660 – phosphoric triester hydrolases MeSH D08.811.277.352.660.500 – aryldialkylphosphatase MeSH D08.811.277.352.700 – ribonucleases MeSH D08.811.277.352.700.350 – endoribonucleases MeSH D08.811.277.352.700.350.025 – aspergillus nuclease s1 MeSH D08.811.277.352.700.350.262 – eosinophil cationic protein MeSH D08.811.277.352.700.350.381 – eosinophil-derived neurotoxin MeSH D08.811.277.352.700.350.500 – micrococcal nuclease MeSH D08.811.277.352.700.350.700 – ribonuclease h, calf thymus MeSH D08.811.277.352.700.350.707 – ribonuclease iii MeSH D08.811.277.352.700.350.711 – ribonuclease p MeSH D08.811.277.352.700.350.715 – ribonuclease, pancreatic MeSH D08.811.277.352.700.350.725 – ribonuclease t1 MeSH D08.811.277.352.700.350.810 – RNA-induced silencing complex MeSH D08.811.277.352.700.375 – exoribonucleases MeSH D08.811.277.352.827 – sulfatases MeSH D08.811.277.352.827.070 – arylsulfatases MeSH D08.811.277.352.827.070.060 – n-acetylgalactosamine-4-sulfatase MeSH D08.811.277.352.827.070.250 – cerebroside-sulfatase MeSH D08.811.277.352.827.070.625 – steryl-sulfatase MeSH D08.811.277.352.827.180 – chondroitinases and chondroitin lyases MeSH D08.811.277.352.827.180.175 – chondroitinsulfatases MeSH D08.811.277.352.827.180.175.060 – n-acetylgalactosamine-4-sulfatase MeSH D08.811.277.352.827.180.175.275 – chondro-4-sulfatase MeSH D08.811.277.352.827.500 – iduronate sulfatase MeSH D08.811.277.352.897 – thiolester hydrolases MeSH D08.811.277.352.897.075 – acetyl-CoA hydrolase MeSH D08.811.277.352.897.700 – palmitoyl-coa hydrolase MeSH D08.811.277.352.897.850 – ubiquitin thiolesterase
=== Hilary Wyndham === Hilary Wyndham (Mark Dexter) is a MD of the FX desk at Pierpoint. Throughout the first season, he is shown to be a more measured leader than his subordinate Kenny, an alcoholic and a bully who repeatedly subjects Yasmin to verbal abuse. However, nearing reduction-in-force (RIF) day, Hilary advises Yasmin not to report Kenny's behavior, telling her that being a "team player" would benefit her career prospects. Yasmin caves to Hilary's advice during her RIF interview when she denies having any negative experiences at Pierpoint, and Hilary vouches for her, ensuring that she is hired. In series 2, Hilary becomes paranoid about contracting COVID-19 at the office, wearing a mask to work and exhibiting germaphobe tendencies. Ironically, it is he who ends up falling ill and having to take time off from the office. Yasmin tells Hilary that she will be spending less time on the FX desk as she explores a move to the Private Wealth Management (PWM) division; Hilary, feeling numb and burnt out from the job, grants her his blessing. Hilary briefly reappears in series 4, now working for the Railways Pension Scheme (RPS); Eric calls him to invest in his and Harper's new short-only fund, SternTao, but Hilary kindly declines, stating that the RPS doesn't share their appetite for risk.
Sources: en.wikipedia.org
A regular working electrode has a radius within an order of magnitude of 1 mm. Having a controlled surface area with a well-defined shape is necessary for being able to interpret cyclic voltammetry results. To run cyclic voltammetry experiments at very high scan rates a regular working electrode is insufficient. High scan rates create peaks with large currents and increased resistances, which result in distortions. Ultramicroelectrodes can be used to minimize the current and resistance. The counter electrode, also known as the auxiliary or second electrode, can be any material that conducts current easily, will not react with the bulk solution, and has a surface area much larger than the working electrode. Common choices are platinum and graphite. Reactions occurring at the counter electrode surface are unimportant as long as it continues to conduct current well. To maintain the observed current the counter electrode will often oxidize or reduce the solvent or bulk electrolyte.
== Strong bases == A strong base is a base that is quantitatively protonated upon exposure to water. This complete protonation is a result of the leveling effect. The term "strong base" can lead to confusion, since in this case "strong" is a category of base rather than a qualitative description. For example, guanidine is a very basic molecule, but it does not meet the definition of a strong base because it is not fully protonated by water. Common examples of strong bases include hydroxides of alkali metals and alkaline earth metals, like sodium hydroxide and calcium hydroxide, respectively. Due to their low solubility, some bases, such as alkaline earth hydroxides, can be used when the solubility factor is not taken into account. One advantage of this low solubility is that "many antacids were suspensions of metal hydroxides such as aluminium hydroxide and magnesium hydroxide"; compounds with low solubility and the ability to stop an increase in the concentration of the hydroxide ion, preventing the harm of the tissues in the mouth, oesophagus, and stomach. As the reaction continues and the salts dissolve, the stomach acid reacts with the hydroxide produced by the suspensions. Strong bases hydrolyze in water completely due to the leveling effect. In this process, the water molecule acts as an acid to protonate the base, resulting in the formation of a hydroxide anion. Under anhydrous conditions, some strong bases can even deprotonate weakly acidic C–H bonds. Here is a list of several strong bases:
Heseltine was unhappy at the way defence contracts were often awarded on a cost-plus basis (i.e. agreeing to pay the supplier a certain amount over and above his costs, leaving no incentive to keep costs to a minimum). In 1985 he promoted his special adviser Peter Levene to be Chief of Defence Procurement; special arrangements had to be made to ensure that Levene did not make decisions affecting his own defence company United Scientific Holdings, of which the former Permanent Secretary Sir Frank Cooper was now chairman, and he was paid £95,000 per annum plus £12,000 in pension contributions, more than the prime minister or senior civil servants. Thatcher agreed to Levene's appointment over civil service objections. He abolished cost-plus pricing of contracts and stated that he had trimmed 10% off the defence equipment budget by 1989 through greater competitive tendering; enough, as Heseltine put it, to pay for the Trident nuclear missile programme. It had been agreed to spend £280m for two Type 22 frigates. Norman Tebbit (Trade and Industry Secretary), with the backing of the Cabinet, wanted them built at Swan Hunter in the North East, but Heseltine threatened resignation in January 1985 unless at least one was built at Cammell Laird on Merseyside, at a cost of an extra £7 million, where Type 22s had been built before. Thatcher let him have his way after he persuaded her that it would reward shipyard workers who had crossed picket lines during a recent strike, but was privately furious, and keen to keep defence costs down in future by buying American equipment.
Sources: en.wikipedia.org
It is a four-amino-acid peptide built from alanine, glutamate, aspartate and glycine in that order. Its formula is C14H22N4O9, and it is made by chemical synthesis rather than extracted from tissue. The synthetic peptide is a single defined molecule, unlike the pineal extracts it is often compared with.
No. The two spellings refer to the same tetrapeptide, and the difference reflects transliteration from Russian. Laboratories and catalogues use both forms interchangeably. The material is also indexed as AEDG, taken from the one-letter codes of its residues.
Epithalamin is a mixed preparation derived from animal pineal tissue and contains many peptides. Epitalon is one synthetic sequence chosen for study from that broader mixture. Statements about one do not transfer directly to the other.
It is a four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine. The chain is unmodified and contains only standard proteinogenic residues, which makes it straightforward to produce by solid-phase synthesis and to characterise by standard peptide methods.